| 摘要 |
We provide for the diagnosis, prognosis and/or treatment monitoring of lung cancer or bronchial dysplasia, and the use thereof for predicting and monitoring therapeutic intervention in dysplasia or cancer patients. According to the invention at least one biomarker selected from the group consisting of APOE, APOC3, A1AT6, A2MG, PROP, TTHY, A1AG8, APOA1, APOH, GPX3, MUP8, RETBP, SAMP, VTDB, S6A11, EGFR, ApoA4, ApoM, a-raf, fetuin B, GSN, PLG, VPS28, and particular peptide sequences derived thereof, is used in the diagnosis, prognosis and/or treatment monitoring of cancer or dysplasia, in particular of lung cancer or the level of at least one of said biomarkers is measured in a body fluid sample, in particular in a blood serum sample, of a patient suffering from or being susceptible to cancer or dysplasia. Within the context of said biomarkers, the invention concerns a composition for qualifying the c-myc activity in a patient suffering or being susceptible to cancer or for classifying a patient suffering from or being susceptible to lung cancer or bronchial dysplasia, in particular by an in vitro body fluid analysis, and a procedure to screen for and to identify drugs against cancer associated with an increased c-myc activity or against dysplasia or cancer associated with an aberrant EGF receptor tyrosine kinase signalling s provided, wherein in a body fluid sample of a transgenic cancer mouse being treated with a compound to be tested at least one of said biomarkers is determined.
|
